PALI · Palisade Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $0 | $0 | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.00M | - | $1.39M | $1.68M | $950.0K | - | $362.0K | $2.63M | $2.21M | - |
| SG&A | $4.35M | - | $1.53M | $1.17M | $1.36M | - | $1.46M | $1.58M | $1.46M | - |
| Total Operating Expenses | $10.75M | - | $2.92M | $2.84M | $2.31M | - | $3.59M | $4.21M | $3.67M | - |
| D&A | $0 | - | - | - | $1.0K | - | - | - | $1.0K | - |
| Operating Income | ($10.75M) | - | ($2.92M) | ($2.84M) | ($2.31M) | - | ($3.59M) | ($4.21M) | ($3.67M) | - |
| Interest Expense | $1.0K | - | $5.0K | $2.0K | $1.0K | - | $6.0K | $2.0K | $1.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($9.60M) | - | ($2.87M) | ($2.78M) | ($2.23M) | - | ($3.49M) | ($4.08M) | ($3.53M) | - |
| EPS - Basic | ($0.05) | - | ($0.38) | ($0.58) | ($0.47) | - | ($2.32) | ($3.32) | ($4.59) | - |
| EPS - Diluted | ($0.05) | - | ($0.38) | ($0.58) | ($0.47) | - | ($2.32) | ($3.32) | ($4.59) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $132.63M | $133.38M | $5.23M | $5.42M | $7.23M | $9.82M | $8.04M | $11.35M | $11.28M | $12.43M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.70M | $767.0K | $1.43M | $1.37M | $745.0K | $1.10M | $366.0K | $514.0K | $459.0K | $698.0K |
| Current Assets | $133.24M | $134.22M | $6.83M | $6.45M | $7.89M | $10.49M | $8.87M | $12.31M | $12.01M | $13.33M |
| Total Assets | $133.31M | $134.34M | $6.97M | $6.67M | $8.19M | $10.88M | $9.34M | $12.87M | $12.65M | $14.05M |
| Current Liabilities | $5.62M | $4.64M | $3.48M | $3.97M | $2.78M | $3.24M | $2.68M | $2.84M | $2.47M | $2.59M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $5.95M | $4.96M | $3.76M | $4.05M | $2.86M | $3.39M | $2.73M | $2.92M | $2.59M | $2.74M |
| Stockholders' Equity | $127.36M | $129.38M | $3.21M | $2.62M | $5.33M | $7.49M | $6.61M | $9.95M | $10.06M | $11.31M |
| Retained Earnings | - | - | - | $141.00M | $138.20M | $135.90M | $132.60M | ($129.10M) | ($125.00M) | $121.50M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.89M) | - | - | - | ($2.33M) | - | - | - | ($3.18M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $3.13M | - | - | - | ($258.0K) | - | - | - | $2.02M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -7.2% | - | -41.1% | -41.8% | -27.2% | - | -37.4% | -31.7% | -27.9% | - |
| Return on equity | -7.5% | - | -89.3% | -106.3% | -41.8% | - | -52.8% | -41.0% | -35.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 23.71 | 28.95 | 1.96 | 1.62 | 2.84 | 3.24 | 3.31 | 4.34 | 4.87 | 5.15 |
| Quick ratio | 23.71 | 28.95 | 1.96 | 1.62 | 2.84 | 3.24 | 3.31 | 4.34 | 4.87 | 5.15 |
| Cash ratio | 23.60 | 28.77 | 1.50 | 1.36 | 2.60 | 3.03 | 3.00 | 4.00 | 4.57 | 4.81 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -10748.0x | - | -584.4x | -1421.5x | -2310.0x | - | -598.8x | -2105.5x | -3673.0x | - |
| Equity multiplier | 1.05 | 1.04 | 2.17 | 2.54 | 1.54 | 1.45 | 1.41 | 1.29 | 1.26 | 1.24 |
| Liabilities / Assets | 0.04 | 0.04 | 0.54 | 0.61 | 0.35 | 0.31 | 0.29 | 0.23 | 0.20 | 0.19 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.9x | - | 2.0x | 1.2x | 0.6x | - | 0.8x | 0.6x | 0.5x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | -100.0% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -365.3% | - | 18.7% | 32.5% | 37.1% | - | 4.9% | -16.7% | -45.2% | - |
| Net income growth (YoY) | -330.5% | - | 17.8% | 31.8% | 36.8% | - | 3.0% | -20.2% | -50.7% | - |
| EPS growth (YoY) | 89.4% | - | 83.6% | 82.5% | 89.8% | - | -373.5% | -526.4% | -750.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 2289.1% | 1626.9% | -51.4% | -73.7% | -47.0% | -33.8% | -53.1% | -37.0% | -26.8% | -9.3% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing PALISADE BIO against the 5 most active filers in the same SIC group.